{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-057711","form_type":"8-K","ticker":"CGTX","cik":"0001455365","company_name":"COGNITION THERAPEUTICS INC","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.484141+00:00","generated_at":"2026-06-02T17:30:57.505089+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cognition Therapeutics Q1 net loss $9.2M; cash runway through Q2 2025; SHINE data mid-2024","bullets":["Net loss of $9.2M ($0.27/share) vs $6.2M ($0.21/share) in Q1 2023.","Cash and equivalents $34.7M plus $62.3M in NIA grant funds; sufficient through Q2 2025.","R&D expenses rose to $10.6M from $5.4M, driven by Phase 2 trial activities.","Topline SHINE (Alzheimer's) results expected mid-2024; SHIMMER (DLB) enrolled 130 participants.","Completed follow-on offering in March 2024, netting $11.9M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-057711","json":"https://secwatch.observer/filing/0001104659-24-057711.json","markdown":"https://secwatch.observer/filing/0001104659-24-057711.md","text":"https://secwatch.observer/filing/0001104659-24-057711.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1455365/000110465924057711/0001104659-24-057711-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1455365/000110465924057711/tm2413335d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T17:30:57.505089+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"67ec20d123d8dbfe01e67b20ff32cada84766990","claim":"COGNITION THERAPEUTICS INC reported first quarter ended March 31, 2024 results: net income $9.2 million, EPS $(0.27) per basic and diluted share.","evidence_excerpt":"The Company reported a net loss of $9.2 million, or $(0.27) per basic and diluted share for the first quarter ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465924057711/0001104659-24-057711-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"$9.2 million"},{"label":"EPS","value":"$(0.27) per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}